Cantor Fitzgerald Analysts Raise Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Cantor Fitzgerald boosted their FY2023 earnings estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, November 14th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of ($2.30) per share for the year, up from their prior forecast of ($2.42). Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.52) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2024 earnings at ($2.30) EPS.

Several other research analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 8th. TD Cowen downgraded shares of Stoke Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 25th. Needham & Company LLC decreased their price objective on shares of Stoke Therapeutics from $25.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Stoke Therapeutics Trading Up 1.2 %

Shares of STOK stock opened at $4.22 on Friday. The stock has a 50 day simple moving average of $4.13 and a 200-day simple moving average of $7.53. The company has a market cap of $188.42 million, a price-to-earnings ratio of -1.74 and a beta of 0.45. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $14.00.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Swiss National Bank raised its position in shares of Stoke Therapeutics by 8.2% during the 1st quarter. Swiss National Bank now owns 30,500 shares of the company’s stock worth $642,000 after purchasing an additional 2,300 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Stoke Therapeutics by 20.8% in the first quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company’s stock worth $412,000 after acquiring an additional 3,374 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Stoke Therapeutics by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after acquiring an additional 837 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Stoke Therapeutics by 58.5% during the first quarter. MetLife Investment Management LLC now owns 11,621 shares of the company’s stock valued at $245,000 after acquiring an additional 4,289 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Stoke Therapeutics by 7.6% during the 1st quarter. Rhumbline Advisers now owns 19,345 shares of the company’s stock worth $407,000 after purchasing an additional 1,362 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.